Two Target Regions of Allelic Loss on Chromosome 9 in Urinary-bladder Cancer

Kenji Ohgaki,1, 2 Kaori Minobe,1 Keisuke Kurose,1 Aritoshi Iida,1 Tomonori Habuchi,1 Osamu Ogawa,1 Yoshinobu Kubota,1 Masao Akimoto2 and Mitsuru Emi1, 5

1Department of Molecular Biology, Institute of Gerontology, Nippon Medical School, 1-396 Kosugi-cho, Nakahara-ku, Kawasaki 211-8533, 2Department of Urology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8602, 3Department of Urology, Faculty of Medicine, Kyoto University, 54 Kawara-machi, Shougoin, Sakyo-ku, Kyoto 606-8507 and 4Department of Urology, Yokohama City University, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004

Allelic losses on chromosome 9 are common in a wide variety of human tumors; moreover, two predisposing loci for some inherited cancer syndromes, i.e., familial malignant melanoma and Gorlin syndrome, have been identified on this chromosome. To define the location of putative tumor suppressor genes involved in cancer of the urinary bladder, 85 bladder cancers were examined for allelic loss at 18 microsatellite loci on chromosome 9. Correlations were also sought between loss of heterozygosity on chromosome 9 and several clinicopathological parameters. Allelic loss was observed in 54 of the tumors (64%) and deletion mapping identified two target regions; one at an interval on 9p21 flanked by D9S736 and D9S165, and the other at an interval on 9q31–34 flanked by D9S58 and D9S61. No subtle mutation was detected in the PTCH gene which lies in the latter interval. Allelic loss on chromosome 9 was observed frequently in low grade and non-invasive tumors as well as in tumors of more advanced phenotype. Inactivation of tumor suppressor genes lying in either of two regions of common deletion identified on chromosome 9 might affect carcinogenic mechanisms at an early stage of tumor development in the urinary bladder.

Key words: Urinary bladder cancer — Chromosome 9 — Loss of heterozygosity — Tumor suppressor gene

Bladder cancer is the most common cancer of the upper urinary tract. Carcinogenesis in human tissues and progression of those tumors are considered to require a series of genetic alterations involving activation of dominant oncogenes and inactivation of tumor suppressor genes. Inactivation of tumor-suppressor functions usually occurs as a consequence of deletion of one allele of a gene involved in control of cell growth, followed by mutation of the other. Therefore, when allelic losses at specific chromosomal loci (loss of heterozygosity, LOH) are observed frequently in a particular type of human cancer, one can infer that putative tumor suppressors are present in normal alleles of those loci and are inactivated by the cancer-associated events causing LOH.1) In cancers of the urinary bladder, LOH has been reported on chromosomes 8, 9, 10, 11, 17, and 18.2–9)

Germ line mutations of tumor suppressor genes confer predispositions to several dominantly inherited cancer syndromes. Two genes in this category have been localized to chromosome 9. On the short arm, cyclin-dependent kinase inhibitor 2 (CDKN2), a gene associated with familial malignant melanoma,10) was isolated recently from 9p21. Homozygous or hemizygous deletions of CDKN2 and/or nearby p15 are also common in cell lines or primary tissues derived from various other types of cancer11, 12) including cancers of the esophagus,13) pancreas14) and urinary bladder.15) On the long arm, the human homologue of the Drosophila “patched” gene (PTCH), whose mutant alleles predispose carriers to nevoid basal cell cancer (Gorlin syndrome), was recently isolated from 9q22.3.16) Somatic mutations and losses of PTCH also have been found in medulloblastomas and meningiomas.17) LOH at yet another region of chromosome 9, q32–33,18) is also frequent in urinary-bladder cancers.

In the study reported here, we undertook to construct a deletion map of chromosome 9 in 85 urinary-bladder cancers by taking advantage of a high-resolution chromosomal map of the region consisting of 18 microsatellite loci. We searched for mutations of PTCH by PCR-single-strand conformation polymorphism (SSCP) analysis, and also compared the frequencies of allelic losses on chromosome 9 with several clinicopathological parameters.

MATERIALS AND METHODS

Samples and DNA preparation Specimens of 85 urinary bladder cancers were obtained, along with paired blood samples as a source of constitutional normal DNA, at Kyoto University Hospital, Yokohama City University Hospital, and Nippon Medical School Hospital. Informed consent of all participating patients were obtained prior to
surgery for urinary-bladder cancer during hospitalization. All of the tumors were classified as transitional-cell cancers. Genomic DNAs were extracted from frozen tissues by a method described previously.19

**LOH analysis**

Eighteen microsatellite markers (D9S178, D9S286, D9S157, D9S736, D9S165, D9S153, D9S287, D9S180, D9S176, D9S58, D9S302, D9S60, D9S61, D9S62, D9S113, D9S66, D9S158) were described in the Genethon comprehensive human linkage map.20, 21 Each polymerase chain reaction (PCR) was performed in a Gene Amp PCR system 9600 (Perkin-Elmer Cetus, Norwalk, CT) using 10 ng of template DNA in a volume of 10 µl, with 30 cycles of 94°C for 30 s, 54–60°C for 30 s, 72°C for 30 s. A 3-µl aliquot of each product was electrophoresed, after which the gels were dried and exposed to X-ray film for 16–48 h.22 Signal intensities of polymorphic alleles were quantified by a Hoefer GS-300 scanning densitometer; peak areas corresponding to each signal were calculated by electric integration using the GS-370 densitometer; peak areas corresponding to each signal were judged to reflect LOH. We also distinguished LOH for sequence variations in all 45 tumors that showed allelic losses on 9q. PCR-SSCP analysis was performed for all coding exons, using PCR designed to amplify 24 overlapping segments. PCR primers for amplification of each exon and all exon-intron boundaries of the **PTCH** gene were described previously by Hahn et al.16 and are presented in Table I. PCR was carried out according to the procedures described previously.23 In brief, each PCR was carried out using 20 ng of genomic DNA extracted from lymphocytes, in a 10-µl solution containing 10 mM Tris-HCl (pH 8.4), 50 mM KCl, 1.5 mM MgCl₂, 0.01% gelatin, 200 µM each of [α-32P]-dCTP (3000 Ci/mmol, 10 µCi/ml), 2.5 pmol of each primer, and 0.25 units of Taq polymerase. Each of the 35 PCR cycles consisted of 30 s at 94°C, 30 s at 60°C, and 30 s at 72°C. Reaction mixtures were diluted with 50 µl of 95% formamide dye and 20 mM EDTA, incubated at 85°C for 5 min, and applied (2 µl/lane) to 6% polyacrylamide gels containing 0.5× TBE (90 mM Tris-borate/2 mM EDTA) and 5% glycerol. Electrophoresis was performed overnight at 100 to 150 V for 16 to 20 h both at room temperature and at 4°C. The gels were dried and autoradiographed with intensifying screens.

**PCR-single strand conformation polymorphism (SSCP)** analysis of the **PTCH** gene

**PTCH** gene was examined for sequence variations in all 45 tumors that showed allelic losses on 9q. PCR-SSCP analysis was performed for all coding exons, using PCR designed to amplify 24 overlapping segments. PCR primers for amplification of each exon and all exon-intron boundaries of the **PTCH** gene were described previously by Hahn et al.16 and are presented in Table I. PCR was carried out according to the procedures described previously.23 In brief, each PCR was carried out using 20 ng of genomic DNA extracted from lymphocytes, in a 10-µl solution containing 10 mM Tris-HCl (pH 8.4), 50 mM KCl, 1.5 mM MgCl₂, 0.01% gelatin, 200 µM each of [α-32P]-dCTP (3000 Ci/mmol, 10 µCi/ml), 2.5 pmol of each primer, and 0.25 units of Taq polymerase. Each of the 35 PCR cycles consisted of 30 s at 94°C, 30 s at 60°C, and 30 s at 72°C. Reaction mixtures were diluted with 50 µl of 95% formamide dye and 20 mM EDTA, incubated at 85°C for 5 min, and applied (2 µl/lane) to 6% polyacrylamide gels containing 0.5× TBE (90 mM Tris-borate/2 mM EDTA) and 5% glycerol. Electrophoresis was performed overnight at 100 to 150 V for 16 to 20 h both at room temperature and at 4°C. The gels were dried and autoradiographed with intensifying screens.

**Table I. Sequences of PTCH Primers Used for PCR-SSCP Analysis**

| Exon | Sense primer (5′–3′) | Antisense primer (5′–3′) | Position (bp) | Size (bp) |
|------|----------------------|--------------------------|---------------|-----------|
| 1    | GAAGGCCAGCACCAGAC   | TCTTTCCTCTCTCTCTCTTCT    | 1–189         | 189       |
| 2    | GTGGACACCGTGAGGTTC   | TCTCCTCCACACCTCTCCTC    | 190–382       | 193       |
| 3    | CTAATTGATATCAATGGGAG | ATTTAGTTAGTGAGGAGGAGG    | 383–582       | 200       |
| 4    | GAGAATTTTGTTCGTCTCTCTTCA | CCGTAGCACCAGAATCTCTCCTTC | 583–642       | 60        |
| 5    | GCAAAAATTTTCTCAGGAAAC | TGGAAACAAACATGTAAGGCAA   | 643–734       | 92        |
| 6    | CCTACAAGGTTGAGCTAGT | TTTGCTCTCCACCTCTCTG    | 735–933       | 199       |
| 7    | GTGACCTGCTACTAATCTCC | GGTAGCAGAGGTAACGGTTTA    | 934–1055      | 122       |
| 8    | GAGCAGCTGGAACACTGTC   | TCTCCTACACACACGACACAC   | 1056–1203     | 148       |
| 9    | GTGCTGTCAGGCTTTG   | ACGGACAGCAGAATGTC       | 1204–1335     | 132       |
| 10   | GTGCTGTCAGGCTTTG    | ACGGACAGCAGAATGTC       | 1336–1492     | 157       |
| 11   | GTGTCGACTGCTGTGGGCA | CTGAGGAAACAGGAGAGCT     | 1493–1591     | 97        |
| 12   | TCTGCCACCGAATTCGTCAC | CTGCCGAGAATTCGCAAGCA   | 1591–1835     | 245       |
| 13   | GCCCTCACCAGCACCAGAC | TTTTGTGAGAGCAGAGAGGCC   | 1836–2238     | 403       |
| 14   | GACAGCTTCTTCCTGTCCAC | AAGGATGAGGATGCTCCTCGT   | 2239–2548     | 310       |
| 15   | AGGGGTCTCCTGGGCTGGGAG | TCGAGGCAGAGGACAGGAGGAGC | 2549–2691     | 143       |
| 16   | AACCACATTCCTCAAGGCTCTGTTC | CACCTGCCTGAAGTCTCCAGACT | 2692–2875     | 185       |
| 17   | AAAGTGATGCTCTCTACCTGGG | AAAATCCCGGCTGAGGAAAAAGA | 2876–3156     | 281       |
| 18   | TTTGCATCGAGCAGGAGGACAC | CAAACAGGAGCAGGAGAATATGG | 3157–3294     | 138       |
| 19   | TAGGACAGAGCTGCAGTGGATTAC | TACGCTGAGAATGACTCG   | 3295–3437     | 143       |
| 20   | TAGGACAGAGCTGCAGTTTACC | TACGCTGAGAATGACTCG   | 3437–3537     | 101       |
| 21   | AACAGAGGCCAATCCCTGAAAAT | GTACAGTCGGTGAGCCGAGGAC | 3538–3792     | 255       |
| 22   | TCTAACCCACCCCTCACCCCTT | ATGGTGGCGGCAGAGATGCCG | 3793–4330     | 537       |

AGAAGGCCGCTTGAGGCCAC | TACCACTCCAGTGAGCTG |
Clinicopathological parameters Tumors were graded according to WHO (World Health Organization) recommendations and staged according to the TNM classification of UICC (Union Internationale Contre le Cancer). The χ² test and Fisher’s exact test were used for statistical analysis of the results. P values of less than 0.05 were considered statistically significant.

RESULTS

LOH was detected in 54 (64%) of the 85 urinary bladder cancers analyzed with 18 polymorphic markers on chromosome 9. The marker loci and their frequencies of LOH are listed in Table II, in descending order from the 9p telomere. Among the 54 tumors with LOH in this chromosome, 38 had lost alleles at all informative loci. Of the others, ten showed partial or interstitial deletions on 9p and seven on 9q.

Representative autoradiograms of cases that showed interstitial or partial deletions of 9p21 or 9q31–34 are presented in Fig. 1. Tumor 64 showed LOH at D9S736 but retained alleles at D9S157 and D9S165. Tumor 68 showed LOH at D9S165 but retained alleles at all informative loci distal to D9S736. Tumor 236 showed LOH at D9S302, but retained alleles at D9S58 and D9S61. Tumor 58 retained alleles at all informative loci proximal to D9S58, but lost alleles at D9S154 and more distal loci.

The results of LOH analysis of the 17 that showed partial or interstitial deletions of chromosome 9 are summarized in Fig. 2. On the p arm, two tumors (tumors 68 and 256) retained heterozygosity at a distal marker, D9S736, but showed LOH at more proximal loci. Four other tumors (tumors 50, 54, 64 and 78) retained heterozygosity at a proximal marker, D9S165, but showed LOH at more distal loci. Hence, we defined the commonly deleted region within the 14-cM interval on 9p21 flanked by D9S736 and D9S165.

On the q arm, tumors 236 and 260 retained heterozygosity at a distal marker, D9S61, but showed LOH at more proximal loci. The proximal limit was defined by D9S58; two tumors (tumors 58 and 236) retained heterozygosity at this locus and showed LOH at a distal marker, D9S154. Hence, we defined this commonly deleted region within the 23-cM interval on 9q31–34 flanked by D9S58 and D9S61. Since the PTCH gene lies in this region we exam-
ined all its coding exons by PCR-SSCP in the 45 tumors that had shown LOH on the 9q arm, but detected no abnormalities (data not shown).

We attempted to correlate LOH on either 9p or 9q with clinicopathological parameters (tumor grade, staging, lymph node metastasis, local recurrence, distant metastas-
sis) in all tumors for which these data were available (Table III). Allelic loss on chromosome 9 was frequent in low grade and non-invasive tumors as well as in tumors of more advanced phenotype.

DISCUSSION

Loss of chromosome 9 is one of the most frequently observed cytogenetic abnormalities in urinary-bladder cancers. We present here the results of high-resolution deletion mapping of 85 primary bladder cancers using 18 microsatellite loci on chromosome 9. Allelic loss was observed in 64% of the tumors in our panel. We identified one target region of common deletion on 9p and another on 9q; the former was defined in the 14-cM interval between D9S736 and D9S165 at 9p21, and the 9q target region constituted the 23-cM interval between D9S58 and D9S61 at 9q31–34.

On deletion mapping of 9p in urinary-bladder cancer, Ruppert et al. located a commonly deleted region between D9S161 (9p21) and the telomere. Cairns et al. localized a commonly deleted region to a 10-cM region at 9p21–22 flanked by D9S162 and D9S171. Orlow et al. observed a high frequency of allelic losses with IFNA marker. Keen et al. described two commonly deleted regions on 9p; a distal region at 9p21 between D9S126 and IFNA and a proximal region at a region centromeric to IFNA. The distal region of that study overlaps with the common regions defined in the former three studies. Simoneau et al., on the hand, defined a commonly deleted region flanked by D9S970 at 9p12 and 9q21, which overlaps with the proximal region of Keen’s study. Czerniak et al. identified two deleted regions on 9p; a distal region at 9p11–13 between D9S268 and D9S285 and a proximal region at 9p21–23 between D9S52 and D9S165. The present study identified a commonly deleted region in a 14-cM interval at 9p21 flanked by D9S736 and D9S165 which overlaps with the proximal region of Czerniak’s study, and provides evidence for the presence of a tumor suppressor gene in the region at 9p21. The commonly deleted region at 9p21 contains the CDKN2 gene, whose mutant alleles, if inherited, predispose carriers to a syndrome of familial malignant melanoma. LOH at 9p21 has been observed in 57–73% of urinary-bladder cancers examined, but this event also is frequent in malignant mesotheliomas, renal-cell cancers, non-small cell lung cancers, and cancers of the nasopharynx, head and neck, and breast. Homozygous deletions of CDKN2 are frequently observed in cancers of the esophagus, pancreas, bladder, and breast, indicating inactivation of both alleles of the gene in those tumors. Baud et al. suggested that simultaneous loss of both CDKN2 alleles, by point mutation or homozygous deletion, was infrequent in primary bladder cancers. In a more recent study, Benedict et al. indicated that loss of CDKN2 protein function could be related to retinoblastoma (RB) protein overexpression by immunohistochemical analysis, since CDKN2 could induce transcriptional down-regulation of RB, and its loss might lead to aberrant RB regulation. Another tumor-suppressor candidate on the short arm is Bcl2-associated gene 1 (BAG1), located at 9p12. The BAG1 protein binds to BCL2 and markedly increases the anti-apoptotic activity of BCL2 induced by various stimuli.

On deletion mapping of 9q in urinary-bladder cancer, Orlow et al. defined a commonly deleted region at 9q34.1–34.2 flanked by D9S10 and D9S7. Habuchi et al. described two commonly deleted regions on 9q in bladder cancer; the proximal region flanked by D9S153 and D9S109, and the distal region flanked by D9S61 and D9S66. Simoneau et al. described a commonly deleted region at 9q21 around D9S283. Czerniak et al. described three commonly deleted regions on 9q; the most proximal region flanked by D9S200 and D9S175 at 9q12–13, the middle region flanked by D9S152 and D9S176 at 9q21–22, and the distal region flanked by ABL1 and D9S158 at 9q34. The commonly deleted regions described in these studies did not overlap with the critical region that we defined between D9S58 and D9S61 in the present study. On the other hand, Keen et al. located a large commonly deleted region that extended over 50 cM from D9S15 to D9S60. Recently, Simoneau et al. identified four unique deleted regions; the most proximal region flanked by D9S201 and D9S180 at 9q22.3, the next proximal region flanked by D9S53 and D9S58 at 9q31–32, the third region flanked by D9S103 and D9S260 at 9q33, and the most distal region flanked by ASS and ABL1 at 9q34. The critically deleted region on 9q in the present study partially overlaps with the region described by Keen et al. and the third region at q33 described by Simoneau et al.

A candidate suppressor gene, named DBCCRI, was recently isolated from a 840 kb YAC present in the overlapping region at 9q32–33. However the absence of mutation in bladder cancer excluded it from candidacy as a tumor suppressor. Therefore, the results of the present study suggest that our commonly deleted region flanked by D9S58 and D9S61 contains an as-yet unidentified tumor suppressor locus. The PTCH gene maps to the vicinity of the commonly deleted region we defined in a 23-cM interval on 9q31–34. PTCH was recently isolated as a predisposing gene for nevoid basal cell cancer (Gorlin syndrome). Somatic mutations and loss of this gene have also been observed in some cutaneous basal-cell cancers, medulloblastomas, and meningiomas. Suzuki et al. screened for mutations throughout the coding region of the PTCH gene using PCR-SSCP in esophageal and lung cancers. They detected two rare polymorphisms in exon 17.
but no somatic mutations in these types of cancer. We did not detect the polymorphism, probably due to the difference in our electrophoretic conditions of SSCP procedures from their study which would have resulted in limited sensitivity in polymorphism detection. Simoneau et al. and Xie et al. screened primary bladder cancers that have LOH on 9q for mutations in the gene but detected no mutations. We examined 45 tumors that showed LOH on 9q for mutations of this gene using PCR-SSCP but detected no mutation, in accord with the former studies. Recently, McGarvey et al. found mutations in two bladder tumors of highly advanced stage and grade (one tumor: pT3b, G3 and the other tumor: pT4, G3) in a panel of 54 primary bladder cancers. Although the latter study might suggest involvement of the \textit{PTCH} gene in a late stage of tumorigenesis in a subset of invasive bladder cancers, from the combined results of these studies, it is unlikely that the \textit{PTCH} gene plays an essential role in the majority of urinary bladder cancers.

There are a number of other known genes on the long arm whose inactivation could lead to uncontrolled cell transformation. For instance, bladder cells and render them prone to neoplastic transformation. \textit{MSSE}, a predisposing gene for multiple self-healing squamous epithelioma, lies at 9q22.2–22.3, a growth arrest-specific gene (\textit{GAS1}) is located at 9q22.3–31, transforming growth factor \(\beta\) receptor-1 (\textit{TGFBRI}) lies at 9q33–34; the tuberous sclerosis-1 gene (\textit{TSC1}) is at 9q34; and the apoptosis-associated protein kinase-1 gene (\textit{DAPK1}) is at 9q34.1. In the present study, the majority of the bladder cancers examined had lost one allele in a large region of 9q. Since deletions as large as 23 cM would cause haplo-insufficiency of most of the growth-controlling genes mentioned above, the deletions of 9q noted here may afford a selective advantage to some urinary bladder cells and render them prone to neoplastic transformation.

\acknowledgments

This work was supported by a special grant-in-aid from the Ministry of Education, Science, Sports and Culture of Japan for priority areas of cancer research, genome science, and Gakujutsu-Frontier, and by a research grant for cancer research from the Ministry of Health and Welfare of Japan.

\receiveddate{April 12, 1999/Revised June 8, 1999/Accepted June 18, 1999}

\references

1) Nakamura, Y. Application of DNA markers to clinical genetics. \textit{Jpn. J. Hum. Genet.}, \textbf{41}, 1–14 (1996).

2) Olumi, A. F., Tsai, Y. C., Nichols, P. W., Skinner, D. G., Cain, D. R., Bender, L. I. and Jones, P. A. Allelic loss of chromosome 17p distinguishes high grade from low grade transitional cell cancers of the bladder. \textit{Cancer Res.}, \textbf{50}, 7081–7083 (1990).

3) Knowles, M. A., Shaw, M. E. and Proctor, A. J. Deletion mapping of chromosome 8 in cancers of the urinary bladder using restriction fragment length polymorphisms and microsatellite polymorphisms. \textit{Oncogene}, \textbf{8}, 1357–1364 (1993).

4) Brewster, S. F., Gingell, J. C., Browne, S. and Brown, K. W. Loss of heterozygosity on chromosome 18q is associated with muscle-invasive transitional cell cancer of the bladder. \textit{Br. J. Cancer}, \textbf{70}, 697–700 (1994).

5) Devlin, J., Keen, A. J. and Knowles, M. A. Homozygous deletion mapping at 9p21 in bladder cancer defines a critical region within 2 cM of IFNA. \textit{Oncogene}, \textbf{9}, 2757–2760 (1994).

6) Habuchi, T., Devlin, J., Elder, P. A. and Knowles, M. A. Detailed deletion mapping of chromosome 9q in bladder cancer: evidence for two tumour suppressor loci. \textit{Oncogene}, \textbf{11}, 1671–1674 (1995).

7) Shaw, M. E. and Knowles, M. A. Deletion mapping of chromosome 11 in cancer of the bladder. \textit{Genes Chromo. Cancer}, \textbf{13}, 1–8 (1995).

8) Takle, L. A. and Knowles, M. A. Deletion mapping implicates two tumor suppressor genes on chromosome 8p in the development of bladder cancer. \textit{Oncogene}, \textbf{12}, 1083–1087 (1996).

9) Kagan, J., Liu, J., Stein, J. D., Wagner, S. S., Babkowski, R., Grossman, B. H. and Katz, R. L. Cluster of allelic losses within a 2.5 cM region of chromosome 10 in high-grade invasive bladder cancer. \textit{Oncogene}, \textbf{16}, 909–913 (1998).
10) Castellano, M. C., Pollock, P. M., Walters, M. K., Sparrow, L. E., Down, L. M., Gabrielli, B. G., Parsons, P. G. and Hayward, N. K. CDKN2A/CDKN2 is inactivated in most melanoma cell lines. *Cancer Res.*, **57**, 4868–4875 (1997).

11) Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavitjian, S. V., Stockert, E., Day, R. S., 3rd, Johnson, B. E. and Skolnick, M. H. A cell cycle regulator potentially involved in genesis of many tumor types. *Science*, **264**, 436–440 (1994).

12) Nobori, T., Miura, K., Wu, D. J., Lois, A., Takabayashi, K. and Carson, D. A. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. *Nature*, **368**, 753–756 (1994).

13) Mori, T., Miura, K., Aoki, T., Nishihara, T., Mori, S. and Nakamura, Y. Frequent somatic mutation of the MTS1/CDK4 (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell cancer. *Cancer Res.*, **54**, 3396–3397 (1994).

14) Caldas, C., Hahn, S. A., da Costa, L. T., Redston, M. S., Schutte, M., Seymour, A. B., Weinstein, C. L., Hrubu, R. H., Yeo, C. J. and Kern, S. E. Frequent somatic mutations and homozygous deletions of the CDKN2 (MST1) gene in pancreatic adenocarcinoma. *Nat. Genet.*, **8**, 27–32 (1994).

15) Gonzalez-Zulueta, M., Shibata, A., Ohnseit, P. F., Spruck, C. H., Ill, Busch, C., Shamaa, M., El-Baz, M., Nichols, P. W., Gonzalgo, M. L. and Elbaz, M. High frequency of chromosome 9p allelic loss and CDKN2 tumor suppressor gene alterations in squamous cell cancer of the bladder. *J. Natl. Cancer Inst.*, **87**, 1383–1393 (1995).

16) Hahn, H., Wicking, C., Zaphiropoulos, P. G., Gailani, M. R., Shanley, S., Chidambaram, A., Vorechovsky, I., Holmberg, E., Unden, A. B., Gillies, S., Negus, K. S., Smyth, I., Pressman, C., Lefflit, D. J., Gerrard, B., Goldstein, A. M., Dean, M., Togtdr, R., Chenevix-Trench, G., Wainwright, B. and Bale, A. E. Mutations of the human homolog of *Drosophila* patched in thenevild basal cell carcinoma syndrome. *Hum. Mol. Genet.*, **7**, 2369–2372 (1997).

18) Habuchi, T., Yoshida, O. and Knowles, M. A. A novel candidate tumour suppressor locus at 9q32–33 in bladder cancer: localization of the candidate region within a single 840 kb YAC. *Hum. Mol. Genet.*, **6**, 913–919 (1997).

19) Okamura, S., Koyama, K., Miyoshi, Y., Monden, M. and Takami, M. Novel germline mutations of hMSH2 in a patient with hereditary nonpolyposis colorectal cancer (HNPCC) and in a patient with six primary cancers. *J. Hum. Genet.*, **43**, 143–145 (1998).

20) Buetow, K. H., Weber, J. L., Lundwigsen, S., Scherphof-Heddeke, T., Duyk, G. M. and Scheffield, V. C. Integrated human genome-wide maps constructed using the CEPH reference panel. *Nat. Genet.*, **6**, 391–393 (1994).

21) Gyapay, G., Morissette, J., Vignal, A., Dib, C., Fizames, C. and Millasseau, P. The 1993–94 Généthon human genetic linkage map. *Nat. Genet.*, **7**, 246–339 (1994).

22) Nakura, J., Miki, T., Ye, L., Mitsuda, N., Ogihara, T., Ohta, T., Jinno, Y., Nikawa, N., Takahashi-Fujii, A. and Ishino, Y. Six dinucleotide repeat polymorphisms on chromosome 7. *Jpn. Hum. Genet.*, **39**, 447–449 (1994).

23) Hirayama, T., Yamaki, E., Hata, A., Tsuji, M., Hashimoto, K., Yamamoto, M. and Eimi, M. Five familial hypercholesterolemic kindreds in Japan with novel mutations of the LDL receptor gene. *J. Hum. Genet.*, **43**, 250–254 (1998).

24) World Health Organization. “In Histological Classification of Tumors No. 10” (1973). WHO, Geneva.

25) “Union Internationale Contre le Cancer,” 3rd Ed. (1978). International Union against Cancer, Geneva.

26) Ruppert, J. M., Tokino, K. and Sidransky, D. Evidence for two bladder cancer suppressor loci on human chromosome 9. *Cancer Res.*, **53**, 5093–5095 (1993).

27) Cairns, P., Tokino, K., Eby, Y. and Sidransky, D. Homozygous deletion of 9p21 in primary human bladder tumors detected by comparative multiplex polymerase chain reaction. *Cancer Res.*, **54**, 1422–1424 (1994).

28) Orlow, I., Lianes, P., Lacombe, L., Dalbagni, G., Reuter, V. E. and Cordon-Cardo, C. Chromosome 9 allelic losses and microsatellite alterations in human bladder tumors. *Cancer Res.*, **54**, 2848–2851 (1994).

29) Keen, A. J. and Knowles, M. A. Definition of two regions of deletion on chromosome 9 in carcinoma of the bladder. *Oncogene*, **9**, 2083–2088 (1994).

30) Simonneau, A. R., Spruck, C. H., 3rd, Gonzalez-Zulueta, M., Gonzalgo, M. L., Chan, M. F., Tsai, Y. C., Dean, M., Steven, K., Horn, T. and Jones, P. A. Evidence for two tumor suppressor loci associated with proximal chromosome 9p to q and distal chromosome 9q in bladder cancer and the initial screening for GAS1 and PTC mutations. *Cancer Res.*, **56**, 5039–5043 (1996).

31) Czernecki, B., Chaturvedi, V., Li, L., Hodges, S., Johnston, D. R., Roy, J. Y., Luthra, R., Logothetis, C., Von Eschenbach, A. C., Grossman, H. B., Benedict, W. F. and Batsakis, J. G. Superimposed histologic and genetic mapping of chromosome 9 in progression of human urinary bladder neoplasia: implications for a genetic model of multistep urothelial carcinogenesis and early detection of urinary bladder cancer. *Oncogene*, **18**, 1185–1196 (1999).

32) Stadler, W. M., Sherman, J., Bohlander, S. K., Roulston, D., Dreyling, M., Rukstails, D. and Olopad, O. I. Homozygous deletion within chromosomal bands 9p21–22 in bladder cancer. *Cancer Res.*, **54**, 2060–2063 (1994).

33) Orlow, I., Lacombe, L., Hannon, G. J., Serrano, M., Pellicer, I., Dalbagni, G., Reuter, V. E., Zhang, Z. F., Beach, D. and Cordon-Cardo, C. Deletion of the CDKN2 and p15 genes in human bladder tumors. *J. Natl. Cancer Inst.*, **87**, 1524–1529 (1995).

34) Williamson, M. P., Elder, P. A., Shaw, M. E., Devlin, J. and Knowles, M. A. p16 (CDKN2) is a major deletion target at 9p21 in bladder cancer. *Hum. Mol. Genet.*, **4**, 1569–1577 (1995).
35) Bjorkqvist, A. M., Tammilehto, L., Anttila, S., Mattsson, K. and Knuutila, S. Recurrent DNA copy number changes in 1q, 4q, 6q, 9p, 13q, 14q and 22q detected by comparative genomic hybridization in malignant mesothelioma. *Br. J. Cancer*, **75**, 523–527 (1997).

36) Cairns, P., Tokino, K., Eby, Y. and Sidransky, D. Localization of tumor suppressor loci on chromosome 9 in primary human renal cell cancers. *Cancer Res.*, **55**, 224–227 (1995).

37) Merlo, A., Gabrielson, E., Askin, F. and Sidransky, D. Frequent loss of chromosome 9p in human primary non-small cell lung cancer. *Cancer Res.*, **54**, 640–642 (1994).

38) Huang, D. P., Lo, K. W., van Hasselt, C. A., Woo, J. K. S., Choi, P. H. K., Leung, S. F., Cheung, S. T., Cairns, P., Sidransky, D. and Lee, J. C. A region of homozygous deletion on chromosome 9p21–22 in primary nasopharyngeal cancer. *Cancer Res.*, **54**, 4003–4006 (1994).

39) van der Reit, P., Nawroz, H., Hruban, R. H., Corio, R., Tokino, K., Koch, W. and Sidransky, D. Frequent loss of chromosome 9p21–22 early in head and neck cancer progression. *Cancer Res.*, **54**, 1156–1158 (1994).

40) An, H. X., Niederacher, D., Picard, F., van Roeyen, C., Bender, H. G. and Beckmann, M. W. Frequent allele loss on 9p21–22 defines a smallest common region in vicinity of the CDKN2 gene in sporadic breast cancer. *Genes Chromosom. Cancer*, **17**, 14–20 (1996).

41) Baud, E., Catilina, P. and Bignon, Y. J. p16 involvement in primary bladder tumors: analysis of deletions and mutations. *Int. J. Oncol.*, **14**, 441–445 (1999).

42) Benedict, W. F., Lerner, S. P., Zhou, J., Shen, X., Tokunaga, H. and Czerniak, B. Level of retinoblastoma protein expression correlates with p16 (MTS-1/INK4A/CDKN2) status in bladder cancer. *Oncogene*, **18**, 1197–1203 (1999).

43) Takayama, S., Sato, T., Krajewski, S., Kochel, K., Irie, S., Millan, J. A. and Read, J. C. Cloning and functional analysis of BAG-1: a novel Bcl-2-binding protein with anti-cell death activity. *Cell*, **80**, 279–284 (1995).

44) Simonene, M., Aboulkassim, T. O., LaRue, H., Rousseau, F. and Fradet, Y. Four tumor suppressor loci on chromosome 9q in bladder cancer: evidence for two novel candidate regions at 9q22.3 and 9q31. *Oncogene*, **18**, 157–163 (1999).

45) Habuchi, T., Luscombe, M., Elder, P. A. and Knowles, M. A. Structure and methylation-based silencing of a gene (DBCCR1) within a candidate bladder cancer tumor suppressor region at 9q32–q33. *Genomics*, **48**, 277–288 (1998).

46) Suzuki, K., Daigo, Y., Fukuda, S., Tokino, T., Isomura, M., Isono, K., Wainwright, B. and Nakamura, Y. No evidence of mutation in the human *PTC* gene, responsible for nevoid basal cell carcinoma syndrome, in human primary squamous cell carcinomas of the esophagus and lung. *Jpn. J. Cancer Res.*, **88**, 225–228 (1997).

47) McGarvey, T. W., Maruta, Y., Tomaszewski, J. E., Linnenbach, A. J. and Malkowicz, S. B. *PTCH* gene mutations in invasive transitional cell carcinoma of the bladder. *Oncogene*, **17**, 1167–1172 (1998).

48) Vellucci, V. F. and Reiss, M. Cloning and genomic organization of the human transforming growth factor-beta type I receptor gene. *Genomics*, **46**, 278–283 (1997).

49) van Slegtenhorst, M., de Hooft, R., Hermans, C., Nellist, M., Janssen, B., Verhoeof, S., Lindhout, D., van den Ouweland, A., Halley, D., Young, J., Burle, M., Jeremia, S., Woodward, K., Nahmias, J., Fox, M., Ekong, R., Osborne, J., Wolfe, J., Povey, S., Snell, R. G., Cheadle, J. P., Jones, A. C., Tachataki, M., Ravine, D. and Kwiatkowski, D. J. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. *Science*, **277**, 805–808 (1997).

50) Feinstein, E., Druck, T. and Kastury, K. Assignment of DAP1 and DAPK—genes that positively mediate programmed cell death triggered by IFN-γ—to chromosome regions 5p12.2 and 9q34.1, respectively. *Genomics*, **29**, 305–307 (1995).

51) Cairns, P., Shaw, M. E. and Knowles, M. A. Initiation of bladder cancer may involve deletion of a tumour-suppressor gene on chromosome 9. *Oncogene*, **8**, 1083–1085 (1993).

52) Miyao, N., Tsai, Y. C., Lerner, S. P., Olumi, A. F., Spruck, C. H., III, Gonzalez-Zulueta, M., Nichols, P. W., Skinner, D. G. and Jones, P. A. Role of chromosome 9 in human bladder cancer. *Cancer Res.*, **53**, 4066–4070 (1993).